TLDR Clascoterone may be a promising treatment for hair loss.
The authors propose that clascoterone, a novel androgen receptor inhibitor, may be a promising treatment for androgenetic alopecia. Clascoterone antagonizes dihydrotestosterone (DHT) through competitive binding with cytoplasmic androgen receptors, and DHT is known to play a causal role in the development of androgenetic alopecia. Clascoterone has been found to have the same efficacy as finasteride in vitro and preliminary industry studies demonstrate a hair growth signal comparable with established treatments such as minoxidil. The authors suggest that clascoterone presents a promising therapeutic avenue for this commonly encountered condition.
3 citations,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
152 citations,
October 2010 in “Archives of Dermatology” Finasteride helps hair growth but may cause sexual side effects.
[object Object]
1 citations,
January 2022 in “Journal of Biosciences and Medicines” Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
July 2023 in “JAAD International” Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.
[object Object] August 2024 in “Cosmetics” Personalized treatments for hair loss are becoming more effective by using genetic information.
19 citations,
August 2019 in “Expert Opinion on Therapeutic Targets” New treatments for hair loss may target specific pathways and generate new hair follicles.
